Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
81-100 of 998 trials

Advanced Hepatobiliary Cancer: New Immunomodulators

We are studying new immunomodulators to see if they can improve treatment outcomes for patients with advanced hepatobiliary cancer. This includes testing their safety and effectiveness alone and with other cancer therapies.

Bile Duct CancerGallbladder CancerHepatocellular Carcinoma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHepatologyOncology

Alpha-Thalassemia: Luspatercept Treatment Study

We are investigating whether Luspatercept can improve anemia in adults and adolescents with Alpha-thalassemia. The study will also assess the safety of this treatment in younger participants.

Alpha ThalassemiaEfficacy phase (II)Post-Trial Drug AccessStandard MedicinesPartially RemoteHematology

Tuberous Sclerosis Complex: mTOR Inhibitor Treatment in Infants

We are studying the effects of a new treatment on brain development in infants with tuberous sclerosis complex. This trial aims to see if the treatment improves cognitive and behavioral outcomes compared to standard care.

Tuberous Sclerosis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

THC Oil for Chronic Neuropathic Pain

We are studying the effects of THC 2% oil on pain relief in patients with chronic neuropathic pain. The trial will also explore how different patient traits may influence the treatment's effectiveness and safety.

Neuropathic Pain≤3 monthsEfficacy phase (II)Investigational MedicinesPartially RemoteInternal MedicineNeurology

Small Cell Lung Cancer: Trilaciclib vs Placebo

We are studying whether trilaciclib can improve survival for patients with extensive stage small cell lung cancer receiving chemotherapy. The trial will also assess its effects on tumor response and safety compared to a placebo.

Extensive Stage Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteOncologyPulmonology

Prostate Cancer: 177Lu-PSMA-617 Treatment Study

We are evaluating whether adding 177Lu-PSMA-617 to standard treatment helps men with metastatic hormone-sensitive prostate cancer who are not responding well to current therapies. The goal is to see if this combination improves survival and disease control.

Hormone-sensitive Metastatic Prostate Cancer3-6 monthsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesPartially RemoteOncologyUrology

Eplontersen for Transthyretin-Mediated Amyloid Cardiomyopathy

We are studying the long-term safety of eplontersen in adults with ATTR-CM. This trial will help us understand how well the treatment is tolerated over an extended period.

Transthyretin-Mediated Amyloid Cardiomyopathy>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Cardiovascular Safety: BI 456906 for Overweight Individuals

We are testing a new medication for people with overweight or obesity and cardiovascular disease to see if it is as safe as a placebo. The study will also look at its effects on blood pressure and waist size.

Obesity>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteCardiologyEndocrinology

Methylmalonic Acidemia: mRNA-3705 Treatment Study

We are testing a new treatment, mRNA-3705, for individuals with isolated Methylmalonic Acidemia. The study aims to evaluate its safety and how well it lowers harmful acid levels in the blood.

Methylmalonic Aciduria>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteEndocrinologyInternal Medicine

Deucravacitinib for Pediatric Plaque Psoriasis

We are studying a new medication for children and teens with moderate to severe plaque psoriasis. The trial will help us understand how well it works and its safety compared to a placebo.

Plaque Psoriasis1-2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteDermatologyPediatrics

Eptinezumab for Pediatric Migraine Prevention

We are studying whether eptinezumab can help reduce the number of migraine days in children and teenagers with episodic migraines. This trial aims to find out if it is a safe and effective option for young patients.

MigraineConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Nipocalimab for Children with Generalized Myasthenia Gravis

We are studying a new treatment for children aged 2 to 17 with generalized myasthenia gravis who are not getting enough benefit from their current therapy. The trial will help us learn about its safety and effectiveness.

Myasthenia Gravis6-12 monthsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNeurologyPediatrics

Lymphoma Treatment Study: Zanubrutinib vs. Lenalidomide

We are comparing the effectiveness of zanubrutinib combined with anti-CD20 antibodies against lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma. This study aims to find out which treatment works better and is safer.

Marginal Zone LymphomaFollicular Lymphoma>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Ovarian Cancer: NiraParib Maintenance Study

We are studying whether three cycles of chemotherapy followed by the drug niraparib is as effective as six cycles for patients with advanced ovarian cancer. This trial focuses on those who have had their tumors completely removed and are HRD-positive.

Ovarian and Fallopian Tube Cancer>2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Asthma Treatment: Povorcitinib Study

We are evaluating a new medication for adults with moderate to severe asthma that isn't well controlled. The study aims to see if it improves lung function and reduces asthma attacks.

Asthma3-6 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemotePulmonology

Nipocalimab for Pregnancies at Risk of Severe Hemolytic Disease

We are studying whether Nipocalimab can help reduce the risk of fetal anemia in pregnant individuals at risk for severe hemolytic disease of the fetus and newborn. This trial compares the treatment to a placebo to assess its effectiveness.

Hemolytic Disease of the Fetus and Newborn>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsInfectious Diseases

Mifepristone as a Weekly Contraceptive

We are studying the effectiveness and safety of a weekly dose of mifepristone for contraception. This trial also looks at how well patients accept this method and any potential effects on liver function.

Oral Contraception1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGynecology and Obstetrics

Dermatomyositis and Polymyositis: PF-06823859 Study

We are testing a new medication to see if it helps reduce muscle and skin symptoms in adults with active dermatomyositis or polymyositis. This study compares the new treatment to a placebo to evaluate its effectiveness.

Polymyositis and DermatomyositisConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Endometrial Cancer: Durvalumab with Chemotherapy

We are studying a new treatment combining durvalumab with standard chemotherapy for patients with advanced or recurrent endometrial cancer. The goal is to see if this approach improves survival and quality of life compared to chemotherapy alone.

Endometrial Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Advanced Cancer: AZD8205 Treatment Study

We are studying the safety and early effectiveness of AZD8205, both alone and with other cancer treatments, for people with advanced or metastatic solid tumors. This research aims to find the best dose and understand how the drug works in the body.

Breast CancerOvarian CancerEndometrial CancerSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology